(Dmytro “Henry” Aleksandrov, Headline USA) Two of America’s leading tech oligarchs have joined the push to develop microchips that will allow them to control and monitor plebian citizens who might otherwise try to disrupt their globalist plans.
In a scenario befitting the dystopian series Black Mirror, billionaires Bill Gates and Jeff Bezos recently invested in Synchron, a new startup that plans to compete against Elon Musk’s Neuralink in trying to control people’s brains, according to Breitbart.
In March 2021, Synchron founder Tom Oxley, an expert in brain-computer interfaces, met with Bezos in Ojai, Calif., to discuss Oxley’s newly established company.
Synchron said last week that it had raised $75 million, with the Amazon founder’s Bezos Expeditions “contributing a portion of the investment,” Breitbart reported.
Other major contributors included ARCH Venture Partners and Gates Frontier, the venture capital branch of Microsoft co-founder Bill Gates.
Vinod Khosla, the founder of Khosla Ventures and the person who introduced Oxley to Gates, also invested in the company.
Oxley, like Musk, has insisted that the only reason the chip is being developed is that there are people with disabilities who will benefit from allowing multi-billionaires to control their neural systems.
“Brain-computer interfaces, also known as BCIs, have the potential to interpret and stimulate certain areas of the brain and are being explored as a possible treatment for brain injuries,” Breitbart noted.
The new investors all approached Synchron “through the lens of making an impact in neurology in an area of need,” it added.
According to Oxley’s estimate, around 100 million people worldwide with upper limb impairments may potentially benefit from the developing technology.
The recent funding haul more than doubles the company’s prior nest egg, bringing its total in raised capital to around $145 million.
According to Pitchbook, a firm that analyses the startup market, that makes it one of the highest-funded companies in the field of brain–computer interface research.
“While it may be behind companies such as Elon Musk’s Neuralink Corporation and Max Hodak’s Science Corp. in terms of fundraising, it is still far ahead of many other BCI companies,” noted Breitbart
Oxley also found three patients who agreed to become laboratory rats as part of a U.S. trial, two of whom already have received the implant with the other expected to do so “in the coming months.”
It hopes the trial will help it garner attention from the Food and Drug Administration, which already helped streamline Synchron’s approval process by granting it “breakthrough” status.
